Cambridge Hepatology Research Seminars
- Stefan Marciniak, University of Cambridge.
- How does Z alpha1-antitrypsin impair cellular function?
The Zoom details for this seminar are:
Join Zoom Meeting
Meeting ID: 913 4460 2150
Future scheduled seminars:
- 8th November, Thomas Marjot, University of Oxford. Circadian rhythm and misalignment in the pathogenesis of NAFLD and metabolic dysfunction.
Zoom details for subsequent seminars will be posted here and mailed out. The timetable of speakers for the rest of the year can be found here.
Clinical studies and trials at Cambridge
Primary biliary cholangitis
Primary sclerosing cholangitis
- LIFT study (closed to recruitment)
Clinical studies and trials at Basildon
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices trial
Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid (NUT-2)
ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis
Clinical studies and trials at Norwich
|REGENERATE 747-303||Phase 3 double-blind randomized long-term placebo controlled multicentre study evaluating the safety and efficacy of Obeticholic Acid in subjects with Nonalcoholic Steatohepatitis (SR)|
|(861) NUC-5 PSC||Double-blind, randomized, placebo-controlled, phase 111 study comparing norurosodexycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis|
|MGL-3196||A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlld Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis|
|The SPRING Study||A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF CM-101 IN SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS- THE SPRING STUDY|
|PLN-74809||A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclersing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC)|
|UK-AIH Cohort||The United Kingdom Autoimmune Hepatitis Cohort (UKAIH): a multicentre platform for research and translational medicine|
|Research Study into the genetic causes of PSC||A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis (UK-PSC)|
|PaCE||Molecular biomarkers in pancreatic cyst fluid to improve diagnostic accuracy and malignancy risk assessment|
|CALIBRE Study||CArvediloL versus variceal Band ligation in primary pREvention of variceal bleeding in liver cirrhosis|
Areas of research:
Autoimmune liver disease/PBC/PSC: George Mells (Cambridge) and Simon Rushbrook (Norwich)
Hepatocellular carcinoma: Matt Hoare (Cambridge), Vicky Snowdon (Cambridge)
NASH/alcohol: Mike Allison (Cambridge)
Metabolic liver disease: Bill Griffiths (Cambridge)
Liver transplantation: Gwil Webb (Cambridge) and Will Gelson (Cambridge)
Hepatitis: Will Gelson (Cambridge)
Portal hypertension: Vicky Snowdon (Cambridge)
Pulmonary complications of liver disease: Sambit Sen (Luton)
Please make contact if you would like any details regarding the above.